|Articles|April 1, 2001

April 2001
Volume 7
Issue 4

Achieving Control of Diabetic Risk Factors in Primary Care Settings

Author(s)Alain G. Bertoni, MD, MPH

Download PDF: Achieving Control of Diabetic Risk Factors in Primary Care Settings

Articles in this issue

about 25 years ago

Article

Indirect Cost of Ischemic Heart Disease to Employers

about 25 years ago

Article

Cost-Sharing for Prescriptions of Sildenafil and Finasteride: A Case Study in Veteran Patients

about 25 years ago

Article

Effects of Compensation Method on Physician Behaviors

about 25 years ago

Article

Healthy Pregnancy Program in a National Managed Care Organization: Evaluation of Satisfaction and Health Behavior Outcomes

about 25 years ago

Article

Impact of Poorly Controlled Hypertension on Healthcare Resource Utilization and Cost

about 25 years ago

Article

The Effect of Nonsteroidal anti-inflammatory Drugs on the Use of Gastroprotective Medication in People with Arthritis

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Achieving Control of Diabetic Risk Factors in Primary Care Settings

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD